A-1331852
CAS No. 1430844-80-6
A-1331852 ( A1331852;A 1331852 )
Catalog No. M11823 CAS No. 1430844-80-6
A-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
Purity : >98% (HPLC)
Size | Price / USD | Stock | Quantity |
2MG | 59 | In Stock |
|
5MG | 105 | In Stock |
|
10MG | 168 | In Stock |
|
25MG | 348 | In Stock |
|
50MG | 521 | In Stock |
|
100MG | 745 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameA-1331852
-
NoteResearch use only, not for human use.
-
Brief DescriptionA-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM).
-
DescriptionA-1331852 is a potent and selective BCL-XL inhibitor (Ki<10 pM); shows much weaker affinity for BCL-2 (Ki=6 nM), BCL-W (Ki=4 nM), and MCL-1 (Ki=142 nM); selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells (Molt-4 viability IC50=6 nM); demonstrates antitumor efficacy in the Molt-4 xenograft model; orally active.
-
SynonymsA1331852;A 1331852
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2;Bcl-w;Bcl-xL;Mcl-1
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1430844-80-6
-
Formula Weight658.81
-
Molecular FormulaC38H38N6O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 12 mg/mL
-
SMILESCC1=C(C=NN1CC23CC4CC(C2)CC(C4)C3)C5=C(N=C(C=C5)N6CCC7=CC=CC(=C7C6)C(=O)NC8=NC9=CC=CC=C9S8)C(=O)O
-
Chemical Name2-Pyridinecarboxylic acid, 6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
2. Punnoose EA, et al. Mol Cancer Ther. 2016 May;15(5):1132-44.
3. Lucas CM, et al. Leukemia. 2016 Jun;30(6):1273-81.
-
BTSA1
BTSA1 is a BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.
-
Bcl-xL antagonist 2
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
-
Orobol
Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.